INSERM U861, I-Stem, AFM, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, 91100 Corbeil-Essonnes, France.
Université Paris-Saclay, Université d'Evry, U861, 91100 Corbeil-Essonnes, France.
Cells. 2021 Jan 27;10(2):240. doi: 10.3390/cells10020240.
The rapid progress in the field of stem cell research has laid strong foundations for their use in regenerative medicine applications of injured or diseased tissues. Growing evidences indicate that some observed therapeutic outcomes of stem cell-based therapy are due to paracrine effects rather than long-term engraftment and survival of transplanted cells. Given their ability to cross biological barriers and mediate intercellular information transfer of bioactive molecules, extracellular vesicles are being explored as potential cell-free therapeutic agents. In this review, we first discuss the state of the art of regenerative medicine and its current limitations and challenges, with particular attention on pluripotent stem cell-derived products to repair organs like the eye, heart, skeletal muscle and skin. We then focus on emerging beneficial roles of extracellular vesicles to alleviate these pathological conditions and address hurdles and operational issues of this acellular strategy. Finally, we discuss future directions and examine how careful integration of different approaches presented in this review could help to potentiate therapeutic results in preclinical models and their good manufacturing practice (GMP) implementation for future clinical trials.
干细胞研究领域的快速进展为其在再生医学应用中修复受损或患病组织奠定了坚实的基础。越来越多的证据表明,基于干细胞的治疗的一些观察到的治疗效果是由于旁分泌作用,而不是移植细胞的长期植入和存活。鉴于它们能够穿越生物屏障并介导生物活性分子的细胞间信息传递,细胞外囊泡正被探索作为潜在的无细胞治疗剂。在这篇综述中,我们首先讨论了再生医学的最新进展及其目前的局限性和挑战,特别关注多能干细胞衍生产品修复眼睛、心脏、骨骼肌和皮肤等器官。然后,我们专注于细胞外囊泡的新兴有益作用,以减轻这些病理状况,并解决这种无细胞策略的障碍和操作问题。最后,我们讨论了未来的方向,并研究了如何仔细整合本综述中提出的不同方法,以帮助增强临床前模型中的治疗效果,并为未来的临床试验实施良好的生产规范(GMP)。